A detailed history of First Pacific Financial transactions in Bei Gene, Ltd. stock. As of the latest transaction made, First Pacific Financial holds 2 shares of BGNE stock, worth $453. This represents 0.0% of its overall portfolio holdings.

Number of Shares
2
Holding current value
$453
% of portfolio
0.0%

Shares

1 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2025

Apr 23, 2025

BUY
$175.1 - $226.71 $350 - $453
2 New
2 $0

Others Institutions Holding BGNE

About BeiGene, Ltd.


  • Ticker BGNE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 103,700,000
  • Market Cap $23.5B
  • Description
  • BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplas...
More about BGNE
Track This Portfolio

Track First Pacific Financial Portfolio

Follow First Pacific Financial and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of First Pacific Financial, based on Form 13F filings with the SEC.

News

Stay updated on First Pacific Financial with notifications on news.